Fulgent Genetics - FLGT Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fulgent Genetics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" FLGT shares.
View FLGT analyst ratings or view top-rated stocks.

3 brokerages have issued 12-month price targets for Fulgent Genetics' shares. Their FLGT share price forecasts range from $40.00 to $50.00. On average, they predict the company's stock price to reach $45.00 in the next twelve months. This suggests a possible upside of 33.7% from the stock's current price.
View analysts price targets for FLGT or view top-rated stocks among Wall Street analysts.

Fulgent Genetics' stock was trading at $29.78 at the start of the year. Since then, FLGT shares have increased by 13.1% and is now trading at $33.67.
View the best growth stocks for 2023 here.

Fulgent Genetics saw a increase in short interest in January. As of January 15th, there was short interest totaling 1,170,000 shares, an increase of 14.7% from the December 31st total of 1,020,000 shares. Based on an average daily volume of 274,400 shares, the short-interest ratio is presently 4.3 days. Approximately 6.3% of the company's stock are short sold.
View Fulgent Genetics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our FLGT earnings forecast.

Fulgent Genetics, Inc. (NASDAQ:FLGT) released its earnings results on Monday, November, 7th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of ($0.02) by $0.13. The company earned $105.66 million during the quarter, compared to analysts' expectations of $103.70 million. Fulgent Genetics had a trailing twelve-month return on equity of 22.10% and a net margin of 33.82%.

Fulgent Genetics updated its fourth quarter 2022 earnings guidance on Monday, November, 21st. The company provided EPS guidance of for the period. The company issued revenue guidance of $60.00 million-$60.00 million, compared to the consensus revenue estimate of $86.70 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Fulgent Genetics investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), NeoGenomics (NEO), Invitae (NVTA), Block (SQ), JD.com (JD), Marvell Technology (MRVL), Teladoc Health (TDOC) and Editas Medicine (EDIT).

(FLGT) raised $60 million in an IPO on Thursday, September 29th 2016. The company issued 4,600,000 shares at $12.00-$14.00 per share. Credit Suisse and Piper Jaffray served as the underwriters for the IPO and Raymond James and BTIG were co-managers.

Fulgent Genetics trades on the NASDAQ under the ticker symbol "FLGT."

Fulgent Genetics' stock is owned by a number of retail and institutional investors. Top institutional investors include Exchange Traded Concepts LLC (0.19%), New York State Teachers Retirement System (0.09%), SummerHaven Investment Management LLC (0.05%), Yousif Capital Management LLC (0.04%), Comerica Bank (0.04%) and Versor Investments LP (0.03%). Insiders that own company stock include Hanlin Gao, Jian Xie, John C Bolger, Paul Kim and X Cycle LP Tcv.
View institutional ownership trends.

Shares of FLGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of FLGT stock can currently be purchased for approximately $33.67.

Fulgent Genetics (NASDAQ:FLGT) has a market capitalization of $991.24 million and generates $992.58 million in revenue each year. The company earns $507.36 million in net income (profit) each year or $8.70 on an earnings per share basis.

The company employs 645 workers across the globe.

Fulgent Genetics' mailing address is 4978 SANTA ANITA AVENUE, TEMPLE CITY CA, 91780. The official website for the company is www.fulgentgenetics.com. The company can be reached via phone at (626) 350-0537, via email at nborsje@blueshirtgroup.com, or via fax at 626-454-1667.